Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: ICICI Securities Limited

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Strong Performer, Getting Expensive

3295.4000 39.40 (1.21%)

NSE Aug 13, 2025 15:31 PM

43.68% Gain from 52W Low

Volume: 98,394

Dr. Lal Pathlabs Ltd.

08 Aug 2024

3295.40

1.21%

Steady quarter; valuation a bit pricey

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY.

Dr. Lal Pathlabs Ltd. is trading above all available SMAs